45 completed. 45 Phase 2, 9 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 45 | Completed 45 |
| Phase 1 | 9 | Completed 9 |
Follow Peripheral T-cell Lymphoma: new trials by email Literature Review of Peripheral T-cell Lymphoma trials Research Report on Peripheral T-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26) AZD4205 - Peripheral T-cell Lymphoma | Phase 2 | Completed | Dizal Pharmaceuticals | 48 | 2022-03-17 | 2025-07-04 |
| A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression brentuximab vedotin, cyclophosphamide, doxorubicin - Peripheral T-cell Lymphoma | Phase 2 | Completed | Seagen, a wholly owned subsidiary of Pfizer | 82 | 2020-11-12 | 2026-08-13 |
| Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab Letermovir - B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 6 | 2020-09-15 | 2025-02-28 |
| A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Duvelisib - Peripheral T-cell Lymphoma | Phase 2 | Completed | SecuraBio | 156 | 2018-02-22 | 2025-03-07 |
| Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma E7777 - Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma | Phase 2 | Completed | Eisai Co., Ltd. | 45 | 2016-03-28 | 2021-07-15 |
| A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) SP-02L (darinaparsin for injection) - Peripheral T-Cell Lymphoma | Phase 2 | Completed | Solasia Pharma K.K. | 67 | 2016-03-25 | 2024-01-26 |
| Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma romidepsin, lenalidomide, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Completed | Northwestern University | 30 | 2015-06-11 | 2026-06-12 |
| Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL Pembrolizumab - Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 2 | Completed | Dana-Farber Cancer Institute | 82 | 2015-04-01 | 2026-05-18 |
| ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas ALRN-6924 - Solid Tumor, Lymphoma | Phase 1 / Phase 2 | Completed | Aileron Therapeutics, Inc. | 142 | 2014-10-01 | 2026-01-13 |
| Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Pralatrexate injection, Vitamin B12, Folic Acid - Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Completed | Mundipharma K.K. | 25 | 2014-03-01 | 2017-11-09 |
| Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies therapeutic allogeneic lymphocytes, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 2 | Completed | University of Chicago | 77 | 2013-04-04 | 2019-08-07 |
| Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients Romidepsin + Gemcitabine - Peripheral T-cell Lymphoma | Phase 2 | Completed | Fondazione Italiana Linfomi - ETS | 20 | 2013-01-01 | 2019-10-14 |
| Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL) KW-0761 (mogamulizumab) - Peripheral T-Cell Lymphoma | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 38 | 2012-04-01 | 2024-06-17 |
| Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies fludarabine phosphate, melphalan, total-body irradiation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Roswell Park Cancer Institute | 94 | 2012-02-28 | 2019-09-24 |
| Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 43 | 2011-09-01 | 2017-05-19 |
| Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma prednisone, cyclophosphamide, etoposide - Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 2 | Completed | University of Nebraska | 34 | 2011-07-06 | 2023-09-22 |
| Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma panobinostat, laboratory biomarker analysis, western blotting - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Completed | Mayo Clinic | 41 | 2011-01-17 | 2022-05-24 |
| Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma everolimus, lenalidomide, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 58 | 2011-01-10 | 2020-10-22 |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay - Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Wake Forest University Health Sciences | 16 | 2011-01-01 | 2018-09-07 |
| Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Akt inhibitor MK2206, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 60 | 2010-12-01 | 2020-11-04 |
Showing 20 of 45. Sign in to see all of them.
Lymphoma, T-Cell, Peripheral (45) · Immunoblastic Lymphadenopathy (21) · Lymphoma, Large-Cell, Anaplastic (21) · Lymphoma, T-Cell, Cutaneous (21) · Leukemia, Lymphocytic, Chronic, B-Cell (19) · Lymphoma, Large B-Cell, Diffuse (19) · Mycosis Fungoides (19) · Sezary Syndrome (19) · Hodgkin Disease (18) · Lymphoma, B-Cell, Marginal Zone (18) · Lymphoma, Extranodal NK-T-Cell (18) · Lymphoma, Follicular (18) · Lymphoma, Mantle-Cell (18) · Lymphoma, Non-Hodgkin (17) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (17)
Hemic and Lymphatic Diseases (45) · Immune System Diseases (45) · Immunoproliferative Disorders (45) · Lymphatic Diseases (45) · Lymphoproliferative Disorders (45) · Neoplasms by Histologic Type (45) · Neoplasms (44) · Lymphoma (39) · Lymphoma, T-Cell (39) · Lymphoma, Non-Hodgkin (28) · Hematologic Diseases (24) · Leukemia (22) · Leukemia, Lymphoid (22) · Disease Attributes (21) · Lymphadenopathy (21)
Whole-Body Irradiation (9) · Mycophenolic Acid (8) · fludarabine phosphate (8) · Cyclophosphamide (7) · Cyclosporine (7) · Peripheral Blood Stem Cell Transplantation (7) · 10-propargyl-10-deazaaminopterin (4) · Alemtuzumab (4) · Prednisone (4) · Doxorubicin (3) · Gemcitabine (3) · Gene Expression Profiling (3) · Immunohistochemistry (3) · Tacrolimus (3) · mogamulizumab (3)
Fred Hutchinson Cancer Center (8) · Kyowa Kirin Co., Ltd. (3) · Acrotech Biopharma Inc. (2) · Mayo Clinic (2) · National Cancer Institute (NCI) (2) · University of Nebraska (2) · AbbVie (prior sponsor, Abbott) (1) · Aileron Therapeutics, Inc. (1) · Case Comprehensive Cancer Center (1) · Celgene (1) · Dana-Farber Cancer Institute (1) · Dizal Pharmaceuticals (1) · Eisai Co., Ltd. (1) · Fondazione Italiana Linfomi - ETS (1) · King Chulalongkorn Memorial Hospital (1)
United States (35) · Italy (11) · France (6) · United Kingdom (6) · Germany (4) · Japan (4) · Spain (4) · Belgium (3) · Canada (3) · Denmark (3) · Netherlands (2) · Poland (2) · Australia (1) · China (1) · Croatia (1)
Brenda Sandmaier (3) · Ajay Gopal (2) · David Maloney (2) · Adam Lerner, MD (1) · Alain Delmer, MD (1) · Amanda Cashen, MD (1) · Andreas Neubauer, MD (1) · Andreas Viardot, MD (1) · Andrei Shustov, MD (1) · Beata Holkova, MD (1) · Bernard Poiesz, MD (1) · Bertrand Coiffier, MD (1) · Charles Farber, MD (1)
PMID 32499241, PMID 19900571, PMID 22271479, PMID 24456586, PMID 25279222, PMID 25605368, PMID 25605745, PMID 26213141, PMID 26764356, PMID 26921086, PMID 26965915, PMID 27071522, PMID 27418646, PMID 28771889, PMID 30952672, PMID 31917843, PMID 33236943, PMID 34230007, PMID 34670169, PMID 36399518, PMID 36661315, PMID 37319432, PMID 37327113, PMID 42018969
P30CA015704 (6), P01CA018029 (3), P01CA078902 (2), 2008 (1), 2019 (1), N01CM00039 (1), N01CM62202 (1), P30CA016672 (1), P30CA036727 (1), P30CA060553 (1), U10CA021115 (1)